OncoMatch/Clinical Trials/NCT07715630
In Vivo PICX CAR-T Therapy for R/R Multiple Myeloma
Is NCT07715630 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1 trial studies Invivo CAR-T for relapsed or refractory multiple myeloma (rrmm).
Treatment: Invivo CAR-T — This study is an investigator-initiated, single-center, single-arm clinical study with a target population of patients with relapsed or refractory multiple myeloma. It is an early exploratory clinical study evaluating the safety, tolerability, and preliminary efficacy of PICX Injection, an in vivo prepared CAR-T cell therapy, in the treatment of relapsed or refractory multiple myeloma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Multiple Myeloma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: standard treatment regimen
Disease progression after at least 2 prior standard treatment regimens; or poor response to primary therapeutic agents (e.g., immunomodulatory agents, proteasome inhibitors)
Cannot have received: CAR-T therapy or other gene-modified cell therapy
Prior treatment with CAR-T therapy or other gene-modified cell therapy before screening
Lab requirements
Blood counts
Hemoglobin ≥ 60 g/L; ANC ≥ 0.5 × 10⁹/L; Platelet count ≥ 50 × 10⁹/L; Lymphocyte count ≥ 0.5 × 10⁹/L; CD3-positive T-cell absolute count ≥ 0.15 × 10⁹/L
Kidney function
creatinine clearance rate (CrCl) ≥ 30 mL/min (Cockcroft-Gault), or serum creatinine (Scr) ≤ 2.0 × ULN
Liver function
ALT and AST ≤ 3.0 × ULN; total bilirubin (TBIL) ≤ 2.0 × ULN (except for patients with congenital hyperbilirubinemia such as Gilbert's syndrome, in which case direct bilirubin may be ≤ 1.5 × ULN)
Cardiac function
LVEF ≥ 40%; no clinically significant pericardial effusion; no clinically significant ECG abnormalities (e.g., severe arrhythmia, myocardial ischemia, conduction block)
Adequate bone marrow function within 1 month prior to screening: Hemoglobin ≥ 60 g/L; ANC ≥ 0.5 × 10⁹/L; Platelet count ≥ 50 × 10⁹/L; Lymphocyte count ≥ 0.5 × 10⁹/L; CD3-positive T-cell absolute count ≥ 0.15 × 10⁹/L; Adequate vital organ function within 1 month prior to screening: Renal function: CrCl ≥ 30 mL/min (Cockcroft-Gault), or Scr ≤ 2.0 × ULN; Hepatic function: ALT and AST ≤ 3.0 × ULN; TBIL ≤ 2.0 × ULN (except for patients with congenital hyperbilirubinemia such as Gilbert's syndrome, in which case direct bilirubin may be ≤ 1.5 × ULN); Cardiac function: LVEF ≥ 40%; no clinically significant pericardial effusion; no clinically significant ECG abnormalities (e.g., severe arrhythmia, myocardial ischemia, conduction block); Pulmonary function: SpO₂ ≥ 90% without supplemental oxygen
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07715630 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior CAR-T therapy or other gene-modified cell therapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages